Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Company Deals

SciNeuro Pharmaceuticals Licenses Alzheimer’s BBB Antibody Platform to Novartis in $1.5 Billion Deal

Fineline Cube Jan 13, 2026
Company Deals

CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR‑T in Solid Tumors

Fineline Cube Jan 13, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Medical Device

Beijing Balance Medical Technology’s Transcatheter Aortic Valve System Accepted for NMPA Review

Fineline Cube Nov 20, 2023

China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has announced that the National Medical...

Company Deals

Amgen Partners with PostEra for Small-Molecule Drug Discovery Initiative

Fineline Cube Nov 20, 2023

Biopharmaceutical company Amgen (NASDAQ: AMGN) has entered into a drug discovery collaboration with US-based PostEra,...

Company Deals

Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology

Fineline Cube Nov 20, 2023

China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with...

Company Drug

Pfizer and Astellas Pharma Secure FDA Approval for Xtandi in High-Risk Non-Metastatic Prostate Cancer

Fineline Cube Nov 20, 2023

Partners Pfizer (NYSE: PFE) and Astellas Pharma (TSE: 4503) last week received indication extension approval...

Company Drug

Yifan Pharmaceutical’s Subsidiary Receives FDA Approval for Ryzneuta (F-627)

Fineline Cube Nov 20, 2023

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary, Evive Biotech Ltd.,...

Company Drug

AstraZeneca Receives FDA Approval for Truqap in HR-Positive, HER2-Negative Breast Cancer

Fineline Cube Nov 20, 2023

UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced last week that it has received regulatory...

Company Drug

Alphamab Oncology’s JSKN003 ADC: Promising Preliminary Data in Advanced Solid Tumors

Fineline Cube Nov 17, 2023

Alphamab Oncology (HKG: 9966) has released preliminary data from a Phase I clinical study on...

Policy / Regulatory

Final Results of China’s Round 9 Volume-Based Procurement Tender Announced

Fineline Cube Nov 17, 2023

The National Allied Procurement Office has released the finalized results and tender bid allocations for...

Company Drug

BMS’s Augtyro Receives FDA Approval for ROS1-Positive NSCLC

Fineline Cube Nov 17, 2023

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS, NYSE: BMY)...

Drug Policy / Regulatory

CDE Releases 76th Batch of Chemical Generic Reference Preparations

Fineline Cube Nov 17, 2023

The Center for Drug Evaluation (CDE) has released the 76th batch of chemical generic reference...

Company Drug

Yipinhong Pharmacy’s AR882 Shows Promise in Gout Treatment in Phase II Study

Fineline Cube Nov 17, 2023

China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II...

Company Drug

Easton Pharmaceutical Receives FDA Approval for Generic Nalmefene

Fineline Cube Nov 17, 2023

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced receiving Abbreviated New Drug Application (ANDA)...

Deals R&D

University of Hong Kong to Host Infectious Disease Labs by UN’s Vaccine Institute and Cambridge University

Fineline Cube Nov 17, 2023

The University of Hong Kong (HKU) is poised to host new infectious disease laboratories established...

Company

BeiGene Ltd Opens Global Industrialization Base for Small-Molecule Drugs in Suzhou

Fineline Cube Nov 17, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the inauguration of its small-molecule...

Company Drug

Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia

Fineline Cube Nov 17, 2023

Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare...

Company Deals

Jiangxi Rimag Group Eyes Hong Kong IPO to Expand Medical Imaging Services

Fineline Cube Nov 17, 2023

Jiangxi Rimag Group Co., Ltd (HKG: 2522), a China-based medical imaging specialist, is planning an...

Company Drug

Vertex Pharmaceuticals and CRISPR Therapeutics Receive Conditional Approval for CRISPR Gene-Editing Therapy

Fineline Cube Nov 17, 2023

Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) have received conditional approval from the...

Company Deals

Q32 Bio Reclaims Development Rights to Anti-IL-7Rα Biologic from Amgen

Fineline Cube Nov 17, 2023

Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights...

Company Deals

Daewoong Pharma and Meheco International Expand Partnership for China’s Market Entry

Fineline Cube Nov 16, 2023

Daewoong Pharma (KRX: 069620), a leading South Korean pharmaceutical company, has reportedly signed a memorandum...

Company Drug

SinoMab BioScience’s Suciraslimab IND Accepted for Review by China’s NMPA

Fineline Cube Nov 16, 2023

SinoMab BioScience Ltd (HKG: 3681), a Hong Kong-based biotechnology company, has announced that the National...

Posts pagination

1 … 384 385 386 … 608

Recent updates

  • RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones
  • Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China
  • Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab
  • Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations
  • SciNeuro Pharmaceuticals Licenses Alzheimer’s BBB Antibody Platform to Novartis in $1.5 Billion Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Company Medical Device

Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China

Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.